CN109908344A - A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis - Google Patents
A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis Download PDFInfo
- Publication number
- CN109908344A CN109908344A CN201711314835.4A CN201711314835A CN109908344A CN 109908344 A CN109908344 A CN 109908344A CN 201711314835 A CN201711314835 A CN 201711314835A CN 109908344 A CN109908344 A CN 109908344A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- ulcerative colitis
- treating
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 41
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 39
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 32
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 32
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 31
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 24
- 241001313857 Bletilla striata Species 0.000 claims abstract description 24
- 241000218176 Corydalis Species 0.000 claims abstract description 24
- 241001252483 Kalimeris Species 0.000 claims abstract description 24
- 229940116229 borneol Drugs 0.000 claims abstract description 24
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 24
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 16
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 15
- 235000019441 ethanol Nutrition 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 9
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims abstract description 4
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 19
- 241000287828 Gallus gallus Species 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 11
- 230000001900 immune effect Effects 0.000 claims description 9
- 241000222122 Candida albicans Species 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000590002 Helicobacter pylori Species 0.000 claims description 8
- 241000194017 Streptococcus Species 0.000 claims description 8
- 229940095731 candida albicans Drugs 0.000 claims description 8
- 229940037467 helicobacter pylori Drugs 0.000 claims description 8
- 230000002949 hemolytic effect Effects 0.000 claims description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 241000272201 Columbiformes Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 230000003014 reinforcing effect Effects 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 210000000689 upper leg Anatomy 0.000 claims description 4
- 206010061926 Purulence Diseases 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000035939 shock Effects 0.000 abstract description 8
- -1 alumen Chemical compound 0.000 abstract description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Abstract
The present invention provides a kind of pharmaceutical compositions and preparation method thereof for treating ulcerative colitis, are related to drug field.The pharmaceutical composition includes: Yolk immunoglobulin composition, kalimeris, rhizoma corydalis, Divine Comedy, borneol, alumen, acetylsalicylic acid, the bletilla striata, Sculellaria barbata.Preparation method includes: to mix kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata, mixes according to solid-liquid ratio 1:6~8 with 40~50% ethyl alcohol, extracts to obtain medical fluid using sound wave shock extraction method；After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, is dried in vacuo.The pharmaceutical composition has good curative effect to the ulcerative colitis of the unknown cause of disease, and has the characteristics that rapid-action, curative effect is good, is not likely to produce drug resistance.
Description
Technical field
The present invention relates to drug fields, in particular to a kind of for treating the pharmaceutical composition of ulcerative colitis
And preparation method thereof.
Background technique
Ulcerative colitis is a kind of colon that the cause of disease is not still fully aware of and rectum chronic nonspecific inflammation disease,
Lesion is confined to colorectal mucosa and submucosa.Lesion multidigit also may extend to colon descendens or even whole in sigmoid colon and rectum
A colon.Symptom is discharged the excrement containing blood, purulence and mucus, is often accompanied by paroxysmal spastic colon pain based on diarrhea, and
It is tenesmus, alleviation can be obtained after defecation.The course of disease is very long, normal recurrent exerbation.This disease sees any age, but 20~30 years old most
See.
It is less for treating the drug of this agnogenic ulcerative colitis currently on the market, and this similar drug is cured
Phase is longer, unsatisfactory curative effect, cannot eliminate the pain of patient in a short time, improve the sense of discomfort of patient.
Summary of the invention
The first object of the present invention is to provide a kind of for treating the pharmaceutical composition of ulcerative colitis, the medicine group
Closing object has good curative effect to the ulcerative colitis of the unknown cause of disease, and with rapid-action, curative effect is good, is not likely to produce drug resistance
Feature.
The second object of the present invention is to provide a kind of for treating the preparation side of the pharmaceutical composition of ulcerative colitis
Method, medicinal material used in the preparation method is cheap and easy to get, and preparation method is simple, and obtained pharmaceutical composition quality is high, drug effect
It is good.
In order to realize above-mentioned purpose of the invention, the following technical scheme is adopted:
It is a kind of for treating the pharmaceutical composition of ulcerative colitis, which includes: according to parts by weight
6~12 parts of Yolk immunoglobulin composition, 5~9 parts of kalimeris, 2~7 parts of rhizoma corydalis, 2~7 parts of Divine Comedy, borneol 5
~9 parts, 2~7 parts of alumen, 2~7 parts of acetylsalicylic acid, 2~7 parts of the bletilla striata, 3~7 parts of Sculellaria barbata.
It is a kind of for treating the preparation method of the pharmaceutical composition of ulcerative colitis, comprising:
According to parts by weight, kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, according to solid-liquid ratio 1:6~8 and 40
~50% ethyl alcohol mixing, extracts to obtain medical fluid using sound wave shock extraction method；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, is dried in vacuo.
Compared with prior art, beneficial effects of the present invention for example,
It is provided by the invention this for treating the pharmaceutical composition of ulcerative colitis, it is combined with Yolk immunoglobulin
Object is active constituent, and can various pathogens be played with good killing effect；Meanwhile the pharmaceutical composition is by from heat-clearing solution
Poison, promoting blood circulation clearing damp, swelling and pain relieving, this four aspect connection of strengthening the spleen and stomach and medication, reduce the wet poison and heat toxin of patient's body, simultaneously
The promoting flow of qi and blood circulation dissipates the stasis of blood, to promote the metabolism of tissue；It is aided with analgesic hemostatic drug, again to mitigate the pain of patient；Finally
It remixes using the drug with strengthening the spleen and stomach, improves healing ability.Pass through a variety of conjunctions having effects that between above-mentioned drug
Reason proportion, the pharmaceutical composition have a good curative effect to the ulcerative colitis of the unknown cause of disease, and have rapid-action, curative effect is good,
The characteristics of being not likely to produce drug resistance.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is
The conventional products that can be obtained by commercially available purchase.
Present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis, and the pharmaceutical composition is by weight
Number meter includes:
6~12 parts of Yolk immunoglobulin composition, 5~9 parts of kalimeris, 2~7 parts of rhizoma corydalis, 2~7 parts of Divine Comedy, borneol 5
~9 parts, 2~7 parts of alumen, 2~7 parts of acetylsalicylic acid, 2~7 parts of the bletilla striata, 3~7 parts of Sculellaria barbata.
According to parts by weight, Yolk immunoglobulin composition is 6~10 parts, kalimeris is 6~8 parts, rhizoma corydalis is 3~5
Part, Divine Comedy are 3~5 parts, borneol is 6~8 parts, alumen is 3~5 parts, acetylsalicylic acid is 3~5 parts, the bletilla striata is 3~5 parts, half
Branch lotus is 4~6 parts.
According to parts by weight, Yolk immunoglobulin composition is 7~9 parts, kalimeris is 6~7 parts, rhizoma corydalis is 4~5
Part, Divine Comedy are 4~5 parts, borneol is 6~7 parts, alumen is 4~5 parts, acetylsalicylic acid is 4~5 parts, the bletilla striata is 4~5 parts, half
Branch lotus is 5~6 parts.
According to parts by weight, Yolk immunoglobulin composition is 8 parts, kalimeris is 7 parts, rhizoma corydalis is 5 parts, Divine Comedy 5
Part, borneol are 7 parts, alumen is 5 parts, acetylsalicylic acid is 5 parts, the bletilla striata is 5 parts, Sculellaria barbata is 6 parts.
Wherein, Yolk immunoglobulin composition is by with A cluster Type B hemolytic streptococcus, Staphylococcus aureus
The strain mixt infection that this six kinds of pathogenic bacteria of bacterium, Pseudomonas aeruginosa, Escherichia coli, helicobacter pylori and Candida albicans are formed
The specific proteins obtained after chicken have the antibacterial action of specificity to this six kinds of pathogenic bacteria, to having very for ulcerative colitis
Good therapeutic effect.
The preparation method of this Yolk immunoglobulin composition includes:
(1) by the bacterium after inactivation treatment according to A cluster Type B hemolytic streptococcus 25~40%, staphylococcus aureus 15
~20%, Pseudomonas aeruginosa 10~15%, Escherichia coli 10~15%, helicobacter pylori 10~15% and Candida albicans 10~
15% ratio mixing, obtains strain mixt；After strain mixt is dissolved, complex antigen is made；
Further, after strain mixt being dissolved, be made complex antigen the step of include: to mix dissolved bacterial strain
Body obtains the full bacterium complex antigen of emulsus, then the full bacterium of emulsus is compound with after not formula adjuvant is mixed according to mass ratio 1:0.5~1.5
Antigen crushing homogenizes.
Further, each bacterium colony ratio of strain mixt is prepared are as follows: A cluster Type B hemolytic streptococcus 30~35%, golden yellow
Color staphylococcus 16~19%, Pseudomonas aeruginosa 12~14%, Escherichia coli 12~14%, helicobacter pylori 12~14% and white
Color candida albicans 12~14%.
(2) complex antigen is injected in chicken and carries out immunologic facilitation, collect the produced egg of chicken for passing through reinforced immunological,
It separates, purify from egg again.
Further, the step of immunologic facilitation is carried out with chicken includes: that complex antigen is injected in the pigeon breast of chicken and big
It is primary every the injection of reinforcing in 8~12 days at leg, it is immunized four times altogether.
Meanwhile the pharmaceutical composition for ulcerative colitis disease also from it is clearing heat and detoxicating, promoting blood circulation clearing damp, swelling and pain relieving,
This four aspect connection of strengthening the spleen and stomach and medication, specifically:
Kalimeris has effects that cooling blood and hemostasis, clearing heat and promoting diuresis, removing toxicity for detumescence.
Rhizoma corydalis has effects that promoting blood circulation, promoting the circulation of qi, analgesic.
Divine Comedy has effects that strengthening the spleen and stomach, promoting digestion and removing indigestion.
Borneol has effects that clearing heat and detoxicating, erosion prevention and muscle growing.
Alumen, the effect for having removing toxic substances desinsection, eliminating dampness antipruritic.
Acetylsalicylic acid has the function of analgesia, anti-inflammatory.
The bletilla striata has effects that astringing to arrest bleeding, detumescence and promoting granulation.
Sculellaria barbata has effects that clearing heat and detoxicating, promoting blood circulation, swelling and pain relieving.
The pharmaceutical composition is by joining and using in terms of clearing heat and detoxicating, promoting blood circulation clearing damp, swelling and pain relieving, strengthening the spleen and stomach this four
Medicine reduces the wet poison and heat toxin of patient's body, while the promoting flow of qi and blood circulation dissipates the stasis of blood, to promote the metabolism of tissue；It is aided with again only
Pain haemostatic medicament, to mitigate the pain of patient；It finally remixes using the drug with strengthening the spleen and stomach, improves healing ability.It is logical
A variety of rational proportions having effects that between above-mentioned drug are crossed, which has the ulcerative colitis of the unknown cause of disease
Good curative effect, and have the characteristics that rapid-action, curative effect is good, be not likely to produce drug resistance.
It is a kind of above-mentioned for treating the preparation method of the pharmaceutical composition of ulcerative colitis comprising:
According to parts by weight, kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, according to solid-liquid ratio 1:6~8 and 40
~50% ethyl alcohol mixing, extracts to obtain medical fluid using sound wave shock extraction method；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, is dried in vacuo.
Further, the power of ultrasonic vibration extraction method is 180~220KHz, or is 190~210KHz, Huo Zhewei
195~205KHz, or be 200KHz；Ultrasonic time is 30~40min, is perhaps 32~38min or is 35min.
Further, it is dried in vacuo as frozen drying method.
This preparation method that present embodiment provides, used medicinal material is cheap and easy to get, and preparation method is simple, obtained
Pharmaceutical composition quality is high, good drug efficacy.
Feature and performance of the invention are described in further detail with reference to embodiments:
Embodiment 1
The present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis comprising:
Yolk immunoglobulin composition 6Kg, kalimeris 9Kg, rhizoma corydalis 7Kg, Divine Comedy 2Kg, borneol 5Kg, alumen 7Kg, second
Acyl salicylic acid 7Kg, bletilla striata 2Kg and Sculellaria barbata 3Kg.
Preparation method includes:
Kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, mixes, adopts with 50% ethyl alcohol according to solid-liquid ratio 1:7
It is extracted to obtain medical fluid with sound wave shock extraction method, the power of ultrasonic vibration extraction method is 200KHz, time 40min；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, is dried in vacuo.
Wherein, the preparation method of Yolk immunoglobulin composition includes:
By the bacterium after inactivation treatment according to A cluster Type B hemolytic streptococcus 25%, staphylococcus aureus 20%, green pus
The ratio mixing of bacillus 15%, Escherichia coli 15%, helicobacter pylori 15% and Candida albicans 10%, obtains bacterial strain mixing
Body；By dissolved strain mixt with after not formula adjuvant is mixed according to mass ratio 1:1.5, the full bacterium complex antigen of emulsus is obtained,
The full bacterium complex antigen crushing of the emulsus is homogenized again, complex antigen is made；
The complex antigen is injected at the pigeon breast and thigh of chicken, it is primary every the injection of reinforcing in 12 days, it is immunized four times altogether,
The produced egg of chicken for passing through reinforced immunological is collected, then separates, purify from the egg.
Embodiment 2
The present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis comprising:
Yolk immunoglobulin composition 10Kg, kalimeris 6Kg, rhizoma corydalis 3Kg, Divine Comedy 5Kg, borneol 8Kg, alumen 3Kg, second
Acyl salicylic acid 3Kg, bletilla striata 5Kg and Sculellaria barbata 6Kg.
Preparation method includes:
Kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, mixes, adopts with 40% ethyl alcohol according to solid-liquid ratio 1:6
It is extracted to obtain medical fluid with sound wave shock extraction method, the power of ultrasonic vibration extraction method is 180KHz, time 35min；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, frozen drying to get.
Wherein, the preparation method of Yolk immunoglobulin composition includes:
By the bacterium after inactivation treatment according to A cluster Type B hemolytic streptococcus 40%, staphylococcus aureus 15%, green pus
The ratio mixing of bacillus 10%, Escherichia coli 15%, helicobacter pylori 10% and Candida albicans 10%, obtains bacterial strain mixing
Body；By dissolved strain mixt with after not formula adjuvant is mixed according to mass ratio 1:0.5, the full bacterium complex antigen of emulsus is obtained,
The full bacterium complex antigen crushing of the emulsus is homogenized again, complex antigen is made；
The complex antigen is injected at the pigeon breast and thigh of chicken, it is primary every the injection of reinforcing in 8 days, it is immunized four times altogether,
The produced egg of chicken for passing through reinforced immunological is collected, then separates, purify from the egg.
Embodiment 3
The present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis comprising:
Yolk immunoglobulin composition 8Kg, kalimeris 7Kg, rhizoma corydalis 5Kg, Divine Comedy 5Kg, borneol 7Kg, alumen 5Kg, second
Acyl salicylic acid 5Kg, bletilla striata 5Kg and Sculellaria barbata 6Kg.
Preparation method includes:
Kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, mixes, adopts with 45% ethyl alcohol according to solid-liquid ratio 1:7
It is extracted to obtain medical fluid with sound wave shock extraction method, the power of ultrasonic vibration extraction method is 210KHz, time 38min；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, frozen drying to get.
Wherein, the preparation method of Yolk immunoglobulin composition includes:
By the bacterium after inactivation treatment according to A cluster Type B hemolytic streptococcus 34%, staphylococcus aureus 18%, green pus
The ratio mixing of bacillus 12%, Escherichia coli 12%, helicobacter pylori 12% and Candida albicans 12%, obtains bacterial strain mixing
Body；By dissolved strain mixt with after not formula adjuvant is mixed according to mass ratio 1:1, the full bacterium complex antigen of emulsus is obtained, then
The full bacterium complex antigen crushing of the emulsus is homogenized, complex antigen is made；
The complex antigen is injected at the pigeon breast and thigh of chicken, it is primary every the injection of reinforcing in 10 days, it is immunized four times altogether,
The produced egg of chicken for passing through reinforced immunological is collected, then separates, purify from the egg.
Embodiment 4
The present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis comprising:
Yolk immunoglobulin composition 6Kg, kalimeris 8Kg, rhizoma corydalis 5Kg, Divine Comedy 3Kg, borneol 6Kg, alumen 5Kg, second
Acyl salicylic acid 5Kg, bletilla striata 3Kg and Sculellaria barbata 4Kg.
Preparation method includes:
Kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, mixes, adopts with 48% ethyl alcohol according to solid-liquid ratio 1:8
It is extracted to obtain medical fluid with sound wave shock extraction method, the power of ultrasonic vibration extraction method is 180KHz, time 40min；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, frozen drying to get.
Wherein, the preparation method of Yolk immunoglobulin composition is as described in Example 3.
Embodiment 5
The present embodiment provides a kind of for treating the pharmaceutical composition of ulcerative colitis comprising:
Yolk immunoglobulin composition 12Kg, kalimeris 5Kg, rhizoma corydalis 2Kg, Divine Comedy 7Kg, borneol 9Kg, alumen 2Kg, second
Acyl salicylic acid 2Kg, bletilla striata 7Kg and Sculellaria barbata 7Kg.
Preparation method includes:
Kalimeris, rhizoma corydalis, Divine Comedy, the bletilla striata and Sculellaria barbata are mixed, mixes, adopts with 43% ethyl alcohol according to solid-liquid ratio 1:7
It is extracted to obtain medical fluid with sound wave shock extraction method, the power of ultrasonic vibration extraction method is 220KHz, time 30min；
After medical fluid is mixed with alumen, borneol again, it is concentrated to give medicinal extract；
Medicinal extract is mixed with Yolk immunoglobulin composition, acetylsalicylic acid again, frozen drying to get.
Wherein, the preparation method of Yolk immunoglobulin composition is as described in Example 3.
Experimental example
Below with reference to clinical test to the pharmaceutical composition provided in 1-5 of the embodiment of the present invention to the trouble of ulcerative colitis
The therapeutic effect of person is evaluated:
One, testing program:
1. case selection:
This group of case is the patients of ulcerative colitis that the course of disease is more than 3 months, meet be included in, exclusion criteria, age 19-
It is 36 years old, 28 years old average.6 groups are randomly divided into, every group each 30, wherein experimental group is the 1st~5 group, and control group is the 6th group.This 6 groups
There was no significant difference for the data such as age, the state of an illness of patient, is comparable.
2. therapeutic scheme:
1st~5 group of (experimental group) patient takes orally the pharmaceutical composition that embodiment 1-5 is provided respectively, daily to take medicine three times, often
The dose of secondary medication is consistent.6th group of (control group) patient is treated using traditional remedies, that is, takes mizoribine.Even
Continuous treatment 2 months, does not use any analgesic drug product during treatment.
The physical condition of observation patient in one week treatment.
3. clinical evaluation standard:
Recovery from illness: under conditions of not depending on drug, the not clinical manifestation of ulcerative colitis；
It is significant: under conditions of taking drugs, the state of an illness of patient is substantially reduced；
It improves: under conditions of taking drugs, the state of an illness of patient has a degree of mitigation；
It is invalid: to refer to that patient does not have to find the change of the state of an illness under conditions of taking the drug.
Two, test result:
It is as shown in table 1:
1. clinical test results of table
| Project | Recovery from illness | Significantly | It improves | In vain |
| Embodiment 1 | 20 | 8 | 2 | 0 |
| Embodiment 2 | 22 | 7 | 1 | 0 |
| Embodiment 3 | 25 | 5 | 0 | 0 |
| Embodiment 4 | 23 | 6 | 1 | 0 |
| Embodiment 5 | 21 | 5 | 3 | 1 |
| Control group | 8 | 16 | 4 | 2 |
As shown in Table 1:
Pharmaceutical composition provided in the present invention is excellent to the therapeutic effect of ulcerative colitis, is mainly manifested in: medication
Later, in the case where no using any anodyne, antibiotic, ulcer can be eliminated, relieved pain, and in Examples 1 to 5
The pharmaceutical composition of offer is high to the treated effect of patient in 2 months, wherein recovery from illness and significant patient account for sum
90% or more, thus illustrate that this pharmaceutical composition is good to the therapeutic effect of ulcerative colitis, with rapid-action, curative effect is good
Feature.
Although illustrate and describing the present invention with specific embodiment, it will be appreciated that without departing substantially from of the invention
Many other change and modification can be made in the case where spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that described pharmaceutical composition is by weight
Number is counted
6~12 parts of Yolk immunoglobulin composition, 5~9 parts of kalimeris, 2~7 parts of rhizoma corydalis, 2~7 parts of Divine Comedy, borneol 5~9
Part, 2~7 parts of alumen, 2~7 parts of acetylsalicylic acid, 2~7 parts of the bletilla striata, 3~7 parts of Sculellaria barbata.
2. according to claim 1 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that by weight
Number meter, the Yolk immunoglobulin composition is 6~10 parts, the kalimeris is 6~8 parts, the rhizoma corydalis is 3~5 parts, institute
State that Divine Comedy is 3~5 parts, the borneol is 6~8 parts, the alumen is 3~5 parts, the acetylsalicylic acid is 3~5 parts, described
The bletilla striata is 3~5 parts, the Sculellaria barbata is 4~6 parts.
3. according to claim 1 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that by weight
Number meter, the Yolk immunoglobulin composition is 7~9 parts, the kalimeris is 6~7 parts, the rhizoma corydalis is 4~5 parts, institute
State that Divine Comedy is 4~5 parts, the borneol is 6~7 parts, the alumen is 4~5 parts, the acetylsalicylic acid is 4~5 parts, described
The bletilla striata is 4~5 parts, the Sculellaria barbata is 5~6 parts.
4. according to claim 1 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that the yolk
The preparation method of immune globulin composite includes:
By the bacterium after inactivation treatment according to A cluster Type B hemolytic streptococcus 25~40%, staphylococcus aureus 15~20%,
Pseudomonas aeruginosa 10~15%, Escherichia coli 10~15%, helicobacter pylori 10~15% and Candida albicans 10~15%
Ratio mixing, obtains strain mixt；After strain mixt dissolution, complex antigen is made；
The complex antigen is injected in chicken and carries out immunologic facilitation, collects the produced egg of chicken for passing through reinforced immunological, then
It separates, purify from the egg.
5. according to claim 4 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that by the bacterium
After strain mixture dissolution, the step of complex antigen is made includes: with not formula adjuvant by dissolved strain mixt according to quality
After mixing than 1:0.5~1.5, the full bacterium complex antigen of emulsus is obtained, then the full bacterium complex antigen crushing of the emulsus is homogenized.
6. according to claim 4 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that with chicken
The step of carrying out immunologic facilitation includes: that the complex antigen is injected at the pigeon breast and thigh of chicken, is infused every reinforcing in 8~12 days
It penetrates once, is immunized four times altogether.
7. according to claim 4 for treating the pharmaceutical composition of ulcerative colitis, which is characterized in that described in preparation
Each bacterium colony ratio of strain mixt are as follows: A cluster Type B hemolytic streptococcus 30~35%, staphylococcus aureus 16~19%, green
Purulence bacillus 12~14%, Escherichia coli 12~14%, helicobacter pylori 12~14% and Candida albicans 12~14%.
8. it is described in any item for treating the preparation method of the pharmaceutical composition of ulcerative colitis according to claim 1~7,
It is characterized in that, comprising:
According to parts by weight, the kalimeris, the rhizoma corydalis, the Divine Comedy, the bletilla striata and the Sculellaria barbata are mixed, according to
Solid-liquid ratio 1:6~8 are mixed with 40~50% ethyl alcohol, extract to obtain medical fluid using ultrasonic vibration extraction method；
After the medical fluid is mixed with the alumen, the borneol again, it is concentrated to give medicinal extract；
The medicinal extract is mixed with the Yolk immunoglobulin composition, the acetylsalicylic acid again, is dried in vacuo.
9. according to claim 8 for treating the preparation method of the pharmaceutical composition of ulcerative colitis, feature exists
In the power of the ultrasonic vibration extraction method is 180~220KHz, and the time is 30~40min.
10. according to claim 8 for treating the preparation method of the pharmaceutical composition of ulcerative colitis, feature exists
In the vacuum drying is frozen drying method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711314835.4A CN109908344A (en) | 2017-12-12 | 2017-12-12 | A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711314835.4A CN109908344A (en) | 2017-12-12 | 2017-12-12 | A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109908344A true CN109908344A (en) | 2019-06-21 |
Family
ID=66957233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711314835.4A Pending CN109908344A (en) | 2017-12-12 | 2017-12-12 | A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109908344A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772999A (en) * | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
| CN1203819A (en) * | 1997-04-23 | 1999-01-06 | 株式会社源 | Prevention and treatment of Enterohemorrhagic Escherichia coli (EHEC) infection |
| US20020025351A1 (en) * | 1997-11-04 | 2002-02-28 | Teikoku Seiyaku Co., Ltd. | Therapeutic agent for treating ulcerative colitis |
| CN1367018A (en) * | 2002-01-28 | 2002-09-04 | 上海高科生物工程有限公司 | Compound preparation of staphylococcolysis enzyme and its preparation method and application |
| CN1457885A (en) * | 2003-06-26 | 2003-11-26 | 雅臣药业集团（远东）有限公司 | Rhinitis and nasosinusitis resisting specific IgY and its combined preparation |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| US20120141458A1 (en) * | 2010-11-23 | 2012-06-07 | Pantheryx, Inc. | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| CN104013958A (en) * | 2014-04-30 | 2014-09-03 | 广州汇高生物科技有限公司 | Specificity yelk immune globulin composition for preventing pathogenic bacteria and preparation thereof |
| CN105214054A (en) * | 2015-10-23 | 2016-01-06 | 朱伟宁 | Be used for the treatment of the Chinese medicine composition of ulcerative colitis |
| CN106810607A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of high-titer Yolk antibody preparation method |
-
2017
- 2017-12-12 CN CN201711314835.4A patent/CN109908344A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772999A (en) * | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
| CN1203819A (en) * | 1997-04-23 | 1999-01-06 | 株式会社源 | Prevention and treatment of Enterohemorrhagic Escherichia coli (EHEC) infection |
| US20020025351A1 (en) * | 1997-11-04 | 2002-02-28 | Teikoku Seiyaku Co., Ltd. | Therapeutic agent for treating ulcerative colitis |
| CN1367018A (en) * | 2002-01-28 | 2002-09-04 | 上海高科生物工程有限公司 | Compound preparation of staphylococcolysis enzyme and its preparation method and application |
| CN1457885A (en) * | 2003-06-26 | 2003-11-26 | 雅臣药业集团（远东）有限公司 | Rhinitis and nasosinusitis resisting specific IgY and its combined preparation |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| US20120141458A1 (en) * | 2010-11-23 | 2012-06-07 | Pantheryx, Inc. | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| CN104013958A (en) * | 2014-04-30 | 2014-09-03 | 广州汇高生物科技有限公司 | Specificity yelk immune globulin composition for preventing pathogenic bacteria and preparation thereof |
| CN105214054A (en) * | 2015-10-23 | 2016-01-06 | 朱伟宁 | Be used for the treatment of the Chinese medicine composition of ulcerative colitis |
| CN106810607A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of high-titer Yolk antibody preparation method |
Non-Patent Citations (5)
| Title |
|---|
| 党炳林: "结肠炎的中医药治疗体会", 《陕西中医学院学报》 * |
| 党炳林: "结肠炎的中医药治疗体会", 《陕西中医学院学报》, vol. 26, no. 4, 31 July 2003 (2003-07-31), pages 17 * |
| 张涛: "健脾清热活血方对溃疡性结肠...-catenin表达的影响", 《广东医学》, vol. 36, no. 21, 30 November 2015 (2015-11-30), pages 3309 - 3314 * |
| 赵浩主编: "《中医急症三宝》", 中国医药科技出版社 * |
| 赵浩主编: "2018全国卫生专业技术资格考试用书 护士执业资格考试应试指南", 中国科学技术出版社, pages: 174 - 175 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698123B (en) | Traditional Chinese medicinal composition for treating transmissible gastroenteritis of swine, feed, preparation method and application thereof | |
| CN110393781A (en) | A kind of pure Chinese medicinal preparation that treating thyroid nodule and preparation method | |
| CN103721103B (en) | Medicine being used for the treatment of pig erysipelas and preparation method thereof | |
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN102085315B (en) | Traditional Chinese medicine composition for treating acute and chronic osteomyelitis | |
| CN101306180A (en) | Gastropathy treating medicine | |
| CN106267193A (en) | A kind of for infusion of medicine agent treating bovine mastitis and its preparation method and application | |
| CN109908344A (en) | A kind of pharmaceutical composition and preparation method thereof for treating ulcerative colitis | |
| CN104523897A (en) | Enteroclysis medicine composition for treating piglet epidemic diarrhea | |
| CN1315513C (en) | Chinese traditional medicine powder medicine for treating milk cow mastitis | |
| CN104257805A (en) | Pharmaceutical composition for treating acute appendicitis | |
| CN101757149A (en) | Pure Chinese herbal compound medicine for preventing fish hemorrhage | |
| CN101129627A (en) | Traditional Chinese medicine formulated product for treating post partum toxin fever | |
| CN103719552B (en) | Feed for preventing and treating swine erysipelas and preparation method for feed | |
| CN105726962A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method thereof | |
| CN105663256A (en) | Ultramicro traditional Chinese medicine for preventing and treating lactation reduction and redness and swelling of breasts of dairy cows | |
| CN109908345A (en) | A kind of pharmaceutical composition and preparation method thereof for treating duodenal ulcer | |
| CN100368003C (en) | Medicine for treating carbuncle and furuncle | |
| CN101554438B (en) | Traditional Chinese medicine for curing hemorrhoids | |
| CN109893649A (en) | A kind of pharmaceutical composition and preparation method thereof for treating gynaecological imflammation | |
| CN101314026B (en) | Serositis in duckling vaccine oral liquid synergistic agent for poultry biology and preparation method thereof | |
| CN109908343A (en) | A kind of pharmaceutical composition and preparation method thereof for treating canker sore | |
| CN109908340A (en) | A kind of antibiosis anti-inflammatory drug compositions and preparation method thereof | |
| CN105213644A (en) | A kind of Chinese medicine preparation for the treatment of acute mastitis and preparation method thereof | |
| CN102406728B (en) | Medicinal composition for treating lymphaden inflammations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190621 |